MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma

Condition:   Metastatic NRAS Melanoma Interventions:   Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1);   Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2);   Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3) Sponsor:   Hospices Civils de Lyon Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials